Cara Therapeutics is a commercial-stage biopharmaceutical company committed to developing and commercializing new chemical entities designed to alleviate pruritus (itch) by selectively targeting kappa opioid receptors (KORs). Their lead product, KORSUVA™ (difelikefalin) injection, is the first and only FDA-approved therapy for moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis. They are also developing an oral formulation of difelikefalin for broader indications, including atopic dermatitis and notalgia paresthetica.
The Stamford headquarters serves as the central hub for Cara Therapeutics' corporate operations, including executive leadership, research and development oversight, clinical development, regulatory affairs, and commercial strategy.
The headquarters likely features modern office spaces designed to foster collaboration and innovation, equipped with facilities to support its administrative and R&D management functions.
As a biopharmaceutical company, the work culture at Cara Therapeutics' headquarters is likely science-driven, patient-focused, and collaborative, emphasizing innovation and regulatory compliance in pursuit of therapeutic advancements.
The Stamford headquarters is strategically important for its access to talent, financial markets, and a network of academic and industry collaborators in the Northeast's biotech corridor.
While headquartered in the USA, Cara Therapeutics has a global focus through its clinical trials conducted in multiple countries and its commercial partnership with Vifor Fresenius Medical Care Renal Pharma for KORSUVA™ (difelikefalin) injection outside the U.S. (ex-Japan and South Korea). Their development programs aim to address medical needs worldwide.
107 Elm Street, 9th Floor
Stamford
Connecticut
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cara Therapeutics' leadership includes:
Cara Therapeutics has been backed by several prominent investors over the years, including:
Cara Therapeutics has experienced significant executive team changes in the past 12-18 months, including the appointment of a new Chief Financial Officer and a new Chief Medical Officer, alongside the transition of its former Chief Scientific Officer.
Discover the tools Cara Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cara Therapeutics most likely utilizes a standard corporate email format, commonly [first_initial][last]@caratherapeutics.com. This is a widely adopted pattern for professional communication.
[first_initial][last]@caratherapeutics.com
Format
jdoe@caratherapeutics.com
Example
80%
Success rate
GlobeNewswire • May 9, 2024
Cara Therapeutics announced its financial results for Q1 2024, highlighting revenue from KORSUVA, progress in its oral difelikefalin programs for atopic dermatitis and notalgia paresthetica, and updates on its pipeline development....more
GlobeNewswire • April 18, 2024
Cara Therapeutics presented new data and analyses for oral difelikefalin in treating moderate-to-severe pruritus in patients with atopic dermatitis at the AAD Annual Meeting, showcasing its potential efficacy and safety....more
GlobeNewswire • January 4, 2024
Cara Therapeutics announced the appointment of Joana Goncalves, M.D., as its new Chief Medical Officer, effective January 2, 2024. Dr. Goncalves brings extensive experience in clinical development and medical affairs to the company....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cara Therapeutics, are just a search away.